Medifron DBT Co. Ltd Cash Flow Conversion Efficiency
Medifron DBT Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Medifron DBT Co. Ltd (065650) has a cash flow conversion efficiency ratio of -0.472x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-12.73 Billion ≈ $-8.63 Million USD) by net assets (₩27.00 Billion ≈ $18.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medifron DBT Co. Ltd (2014–2024)
Cash flow conversion efficiency of Medifron DBT Co. Ltd from 2014 to 2024. This chart illustrates how Medifron DBT Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Medifron DBT Co. Ltd (065650) stock price for real-time trading data and today's change.
Medifron DBT Co. Ltd Cash Flow Conversion Ratio Explained
Medifron DBT Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medifron DBT Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medifron DBT Co. Ltd ranked by their cash flow conversion efficiency. Also see Medifron DBT Co. Ltd stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Neo-Concept International Group Holdings Limited Ordinary Shares
NASDAQ:NCI
|
0.008x |
|
ZIGUP plc
LSE:ZIG
|
0.202x |
|
Nukkleus Inc
NASDAQ:NUKK
|
0.033x |
|
Ruchi Infrastructure Limited
NSE:RUCHINFRA
|
0.089x |
|
Pan Asia Footwear Public Company Limited
BK:PAF
|
0.191x |
|
Intrasense
PA:ALINS
|
0.452x |
|
Acumentis Group Ltd
AU:ACU
|
0.081x |
|
Metacon AB
ST:META
|
-0.611x |
Annual Cash Flow Conversion Efficiency for Medifron DBT Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Medifron DBT Co. Ltd from 2014 to 2024. Review 065650 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩17.49 Billion ≈ $11.85 Million |
₩-4.54 Billion ≈ $-3.07 Million |
-0.259x | -347.44% |
| 2023-12-31 | ₩36.89 Billion ≈ $25.00 Million |
₩-2.14 Billion ≈ $-1.45 Million |
-0.058x | +38.16% |
| 2022-12-31 | ₩31.09 Billion ≈ $21.07 Million |
₩-2.91 Billion ≈ $-1.97 Million |
-0.094x | -163.79% |
| 2021-12-31 | ₩42.29 Billion ≈ $28.66 Million |
₩-1.50 Billion ≈ $-1.02 Million |
-0.036x | +40.87% |
| 2020-12-31 | ₩27.86 Billion ≈ $18.88 Million |
₩-1.67 Billion ≈ $-1.13 Million |
-0.060x | +75.19% |
| 2019-12-31 | ₩17.69 Billion ≈ $11.99 Million |
₩-4.28 Billion ≈ $-2.90 Million |
-0.242x | -445.39% |
| 2018-12-31 | ₩19.20 Billion ≈ $13.01 Million |
₩-852.48 Million ≈ $-577.71K |
-0.044x | +6.08% |
| 2017-12-31 | ₩24.75 Billion ≈ $16.77 Million |
₩-1.17 Billion ≈ $-793.09K |
-0.047x | -4.98% |
| 2016-12-31 | ₩25.57 Billion ≈ $17.33 Million |
₩-1.15 Billion ≈ $-780.62K |
-0.045x | -529.58% |
| 2015-12-31 | ₩23.80 Billion ≈ $16.13 Million |
₩-170.27 Million ≈ $-115.39K |
-0.007x | -25520.44% |
| 2014-12-31 | ₩24.94 Billion ≈ $16.90 Million |
₩701.96K ≈ $475.71 |
0.000x | -- |
About Medifron DBT Co. Ltd
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD… Read more